Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy passes key technological milestone

Researchers at the CERN facility in Geneva working on the company’s LIGHT system have confirmed it is now generating proton beams with sufficient energy to treat superficial tumours
researchers at CERN
The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle'

Advanced Oncotherapy PLC (LON:AVO) said it has passed a key technological milestone on schedule.

Researchers at the CERN facility in Geneva working on the company’s LIGHT system have confirmed it is now generating proton beams with sufficient energy to treat superficial tumours.

“This announcement marks the shift from a complex ‑ albeit well-proven ‑ scientific and physics reality into a medical application with tangible and direct implications for patients,” said chief executive Nicolas Sérandour.

“This very important step supports the confidence we have in delivering our plan and being in a position to offer a system that delivers a better outcome for patients whilst generating more value for the operators."

The results from the work to date showed the LIGHT proton beam technology comfortably treated simulated superficial tumours and marginally deeper cancers.

Healthy tissue, such as the eye and the lens, was spared because of the targeted nature of the device. Dosing was well controlled.

Next target in sight 

The development team is now focused on the “relatively low-execution risk activity” of adding further accelerating modules.

This will ensure the AVO equipment can treat all indications suitable for proton therapy.

“A further technical update will be provided in the next few days,” the company said.

LIGHT stands for Linac Image Guided Hadron Technology. The AVO kit is cheaper and smaller than the current units, which are almost prohibitively expensive.

It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle’.

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

Article
September 28 2018

Related Articles

LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use